A Randomized Double-Blind Phase III Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients With Relap
Posted Date: May 15, 2019
- Investigator: Tahir Latif
- Type of Study: Drug
Alliance A051301
Criteria:
To Be Eligible To Participate In This Study, Patients Must Have A Certain Type Of Diffuse Large B-Ce
Keywords:
A051301, Cancer, Lymphoma, Phase Iii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com